Erasca, Inc. 8-K

What Happened

• Erasca announced a conference call and webcast on April 27, 2026 at 4:30 p.m. ET to discuss preliminary Phase 1 dose‑escalation data for its pan‑RAS molecular glue candidate ERAS‑0015. The live webcast and replay are available at Erasca.com/events (dial‑in: 1‑877‑407‑3982 U.S./Canada; 1‑201‑493‑6780 international).
• On April 24, 2026 Erasca received a letter from counsel for Revolution Medicines, Inc. (RevMed) alleging (1) ERAS‑0015 is “substantially equivalent” to compositions claimed in RevMed’s U.S. Patent No. 12,409,225 (the “’225 Patent”) and infringes under the doctrine of equivalents; (2) misappropriation of RevMed’s alleged trade secrets tied to a patent relating to ERAS‑0015, asserting potential licensee liability; and (3) improper public comparisons between ERAS‑0015 and RevMed’s RMC‑6236. RevMed demanded Erasca immediately cease making, using, offering for sale, selling, and importing ERAS‑0015 in the U.S. outside Hatch‑Waxman safe harbor and stop the comparative statements. Erasca stated it believes the allegations are without merit and intends to contest them vigorously.

Key Details

• Conference call/webcast: April 27, 2026 at 4:30 p.m. ET; webcast/replay at Erasca.com/events.
• RevMed letter dated April 24, 2026 cites U.S. Patent No. 12,409,225 and competitor RMC‑6236.
• RevMed demanded a U.S. cease of ERAS‑0015 activities (except Hatch‑Waxman safe‑harbor uses) and stop comparative statements.
• Erasca publicly rejected the claims and warned investors via customary forward‑looking statement language about litigation risks and uncertainties.

Why It Matters

• For investors, two material items were disclosed: imminent preliminary Phase 1 data for ERAS‑0015 (a potential value driver) and a patent/trade‑secret demand from a competitor that could lead to litigation, delays, or commercial restrictions if escalated.
• The letter is an assertion, not a court filing; Erasca says it will contest the claims. Nonetheless, such disputes can create legal costs, potential injunction or licensing exposure, and uncertainty around development and commercialization timelines—factors investors should monitor alongside the upcoming clinical data release.